Lessons Learned from the Three Commercially Approved ADCs in 2019

8:50 am Chair’s Opening Remarks

9:00 am Polatuzumab Vedotin From Beginning to Approval & Beyond


• Reviewing the discovery of Polatuzumab
• Evaluating early clinical data and gaining approval
• Exploring future combinations

9:20 am PADCEV: An Evolution in the Therapeutic Landscape of Urothelial Cancer

  • Nancy Whiting Executive Vice President, Late Stage Development, Seattle Genetics


• Assessing ADCs as a new therapeutic class in bladder cancer and PADCEV’s unique mechanism of action
• Analyzing data on efficacy/safety of PADCEV in metastatic urothelial cancer and ongoing exploration of its activity in early bladder cancer
• Evaluating PADCEV as an MMAE-class ADC and its potential synergy with immunotherapy

9:40 am The Development & Approval of Enhertu in Patients with Unresectable or Metastatic HER2-positive Breast Cancer

  • Gilles Gallant Senior Vice President, Global Head, Oncology Development, Daiichi Sankyo


• Outlining the pre-clinical profile and mechanism of action of Enhertu ([Fam-] trastuzumab deruxtecan, DS-8201a, T-DXd)
• Reviewing clinical development leading to the approval of Enhertu
• Understanding the current development status of Enhertu

10:00 am Live Discussion & Question Time

  • Andrew Polson Principal Scientist, Genentech
  • Gilles Gallant Senior Vice President, Global Head, Oncology Development, Daiichi Sankyo
  • Nancy Whiting Executive Vice President, Late Stage Development, Seattle Genetics

10:30 am Morning Refreshments & Virtual Speed Networking


Grab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new
contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through
this exclusive virtual speed networking!

This session is a great opportunity to introduce yourself to the attendees that you would like to have more in-depth conversations
with. Get face-to-face time with many of the brightest minds working in the ADC field and establish meaningful business

11:30 am

2:20 pm

3:00 pm Afternoon Refreshments & Networking


An opportunity to virtually walk the exhibition or enjoy the 7th Annual World ADC Awards results

Uncovering the Wave of Next Generation Successful Conjugates

4:00 pm Tumor-Targeted In Situ Immunization; Off-The Shelf & Systemically-Administered


• Re-assessing the role of cytotoxins as stimulators of immunogenic cell death in propogating more robust immune response
• Targeted immunostimulators generate innate immune responses to tumors while increasing systemic tolerability
• Homogeneous combination conjugates of mechanistically different payloads to an antibody opens up systemically administered
“in situ immunisation”

4:20 pm The Journey to Commercializing Antibody Drug Conjugates


  • This presentation will take you through the story of a CMO preparing for the manufacture of a Commercial Antibody Drug Conjugate
  • Join us to learn about how MilliporeSigma grew as a CMO to develop a Commercial ADC platform
  • We will share our story including development platforms for process characterization and validation execution

4:40 pm Tumor Targeting of a STING Agonist by Means of an ADC Induces Anti-Tumor Immune Responses & Immunological Memory


  • Mersana has developed the Immunosynthen platform to enable tumor-targeted delivery of a STING agonist by means of an ADC
  • Demonstrating how targeted STING-agonist ADCs induce potent anti-tumor immune responses and immunological memory
  • Understanding how targeted STING-agonist ADCs cause significantly more anti-tumor activity and dramatically less induction of systemic cytokines than intravenously administered free STING agonist

5:00 pm Live Discussion & Question Time

5:30 pm Chair’s Closing Remarks